scholarly journals Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products

mAbs ◽  
2012 ◽  
Vol 4 (6) ◽  
pp. 761-774 ◽  
Author(s):  
Qingqiao Tan ◽  
Qingcheng Guo ◽  
Chen Fang ◽  
Chong Wang ◽  
Bohua Li ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Tnf Receptor ◽  
Fc Fusion Protein

scholarly journals No Increased Insulin Sensitivity after a Single Intravenous Administration of a Recombinant Human Tumor Necrosis Factor Receptor: Fc Fusion Protein in Obese Insulin-Resistant Patients*

2000 ◽  
Vol 85 (3) ◽  
pp. 1316-1319 ◽  
Author(s):  
Nicolas Paquot ◽  
Manuel J. Castillo ◽  
Pierre J. Lefèbvre ◽  
Andre J. Scheen
Keyword(s):  
Insulin Sensitivity ◽  
Tumor Necrosis Factor ◽  
Glucose Tolerance ◽  
Fusion Protein ◽  
Tumor Necrosis ◽  
Metabolic Clearance ◽  
Tnf Receptor ◽  
Insulin Resistant ◽  
Fc Fusion Protein ◽  
Necrosis Factor

Abstract Inhibition of tumor necrosis factor (TNF)-α results in a marked increase in insulin sensitivity in obese rodents. We investigated the influence of a TNF antagonist [Ro 45-2081, a recombinant fusion protein that consists of the soluble TNF-receptor (p55) linked to the Fc portion of human IgG1] on insulin sensitivity of patients with android obesity. Seven patients (five women and two men; mean ± sd age, 41 ± 4 yr; body mass index, 36.1 ± 4.7 kg/m2; waist to hip ratio, 0.99 ± 0.11) were studied (three patients with normal glucose tolerance and four patients with impaired glucose tolerance or mild diabetes; all were hyperinsulinemic). Each patient underwent two consecutive euglycemic hyperinsulinemic glucose-clamp tests: 48 h after injection of placebo and 48 h after a single iv injection of 50 mg Ro 45-2081. In both tests, steady-state plasma glucose and insulin levels were similar. Insulin-mediated glucose disposal (2.23 ± 0.74 vs. 2.38 ± 0.99 mg/kg−1·min−1) and glucose metabolic clearance rate (2.28 ± 0.85 vs. 2.48 ± 1.03 mL/kg−1·min−1) were similar after placebo and after the drug. Indirect calorimetry showed no difference in substrate oxidation rates between the two experimental conditions. In conclusion, under the conditions of this study, no improvement in insulin sensitivity was observed in obese insulin-resistant patients following a single iv administration of a recombinant TNF receptor: Fc fusion protein.

scholarly journals Characterization and comparison of commercially available TNF receptor 2-Fc fusion protein products

mAbs ◽  
2013 ◽  
Vol 5 (5) ◽  
pp. 624-625 ◽  
Author(s):  
Brian Hassett ◽  
Scott McMillen ◽  
Brian Fitzpatrick
Keyword(s):  
Fusion Protein ◽  
Tnf Receptor ◽  
Fc Fusion Protein

scholarly journals Anti-Tumor Activity and Pharmacokinetics of AP25-Fc Fusion Protein

2019 ◽  
Vol 16 (7) ◽  
pp. 1032-1041
Author(s):  
Dening Pei ◽  
Jialiang Hu ◽  
Chunming Rao ◽  
Pengcheng Yu ◽  
Hanmei Xu ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Fc Fusion Protein ◽  
Anti Tumor Activity

scholarly journals Systemic administration of monovalent follistatin-like 3-Fc-fusion protein increases muscle mass in mice

iScience ◽  
2021 ◽  
pp. 102488
Author(s):  
Takayuki Ozawa ◽  
Masato Morikawa ◽  
Yasuyuki Morishita ◽  
Kazuki Ogikubo ◽  
Fumiko Itoh ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Muscle Mass ◽  
Systemic Administration ◽  
Fc Fusion Protein

scholarly journals Long‐term safety and efficacy of recombinant factor VIII Fc fusion protein (rFVIIIFc) in subjects with haemophilia A

Haemophilia ◽  
2015 ◽  
Vol 22 (1) ◽  
pp. 72-80 ◽  
Author(s):  
B. Nolan ◽  
J. Mahlangu ◽  
D. Perry ◽  
G. Young ◽  
R. Liesner ◽  
...  
Keyword(s):  
Fusion Protein ◽  
Factor Viii ◽  
Recombinant Factor Viii ◽  
Haemophilia A ◽  
Safety And Efficacy ◽  
Fc Fusion Protein
Sign in / Sign up

Export Citation Format

Share Document